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Induction of T-Cell Responses against Cutaneous
T-Cell Lymphomas Ex Vivo by Autologous Dendritic
Cells Transfected with Amplified Tumor mRNA
Xiao Ni1, Heather M. Richmond1, Xingsheng M. Liao1,3, William K. Decker2, Lisa H. Shiue1,
Elizabeth J. Shpall2 and Madeleine Duvic1
Se´zary syndrome (SzS), the leukemic variant of cutaneous T-cell lymphomas, is incurable. Dendritic cells (DCs)
transfected with tumor mRNA can stimulate antitumor immunity in certain cancer patients. In this study, we
determined whether mRNAs from Se´zary cells could be used for loading DCs and stimulating antitumor
immunity. Autologous DCs were generated from monocytes of the peripheral blood from 10 patients with SzS.
Total RNA was extracted from Se´zary cells and amplified by T7 in vitro transcription. The induction of antitumor
IFN-g and granzyme B (GrB)-producing cytotoxic T lymphocytes (CTL) by RNA-transfected DCs was determined
by ELISPOT assays. We found that IFN-g was required for IL-12p70 production by monocyte-derived DCs from
SzS. The oncogenic transcription factor Twist and the tyrosine kinase receptor EphA4 were expressed in total
RNA from Se´zary cells and the paired amplified mRNAs. RNA-transfected DCs induced antitumor IFN-g-
producing CTLs in 7 of 10 subjects and GrB-producing CTLs in 6 of 9 subjects. Both CD3þCD8þ T cells and
CD4þCD25þ T cells were expanded without induction of regulatory T cells. These data support the concept of
using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific
antigens in patients with SzS.
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INTRODUCTION
Cutaneous T-Cell lymphomas (CTCL) are non-Hodgkin’s
lymphomas that present with skin lesions. Mycosis fungoides
(MF), and its erythrodermic leukemic variant, Se´zary syn-
drome (SzS), the most common forms of CTCLs, are charac-
terized by clonal proliferation of malignant, skin-homing,
CD4þCD45ROþ helper/memory T cells with loss of CD7
and CD26 expression (Jones et al., 2001; Kim et al., 2005).
Patients with SzS are reported to have an 11% 5-year survival
rate as compared with the more indolent MF that has an
overall 5-year survival rate of 87% (Willemze et al., 1997). In
the past several years, progress has been made in developing
new treatments, including biological agents denileukin
diftitox (Ontak), antibodies, cytokines, and IFNs (Apisarntha-
narax and Duvic, 2001; Rook et al., 2001; Duvic et al., 2002,
2007). One potential disadvantage of using cytokines or IFNs
as nonspecific immunotherapy is their adverse effects on the
patients’ quality of life.
Dendritic cells (DC), the most potent antigen-presenting
cells, have been used successfully to stimulate antitumor
immune responses that lead to long-term, cell-mediated
immunity and regression of tumors. Patients with SzS exhibit
favorable responses to the DC-based immunotherapy, extra-
corporeal photopheresis (ECP), that was approved in 1987
by the FDA for treatment of erythrodermic MF and SzS
(Edelson, 1984). The overall response rate in SzS patients
treated with traditional ECP is between 54 and 66%, with a
14–33% complete response rate (Jiang et al., 1999; Crovetti
et al., 2000; Duvic et al., 2003; Zic, 2003). Berger et al.
(2001) first reported that ECP worked by inducing tumor
T-cell apoptosis, followed by generation of tumor-loaded
DCs.
Unfortunately, not all CTCL patients respond to ECP and
relapses are common. It has been noted that loss of CD8þ
T cells in MF lesions and peripheral blood of SzS patients
is associated with poor prognosis and inability to respond
to ECP therapy (Heald et al., 1992). Recently, a small trial
of monocyte-derived DCs to vaccinate CTCL patients was
conducted by Maier et al. (2003). Autologous tumor-lysate-
pulsed, monocyte-derived DCs were injected into the lymph
nodes of 10 refractory CTCL patients. Half of them developed
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objective clinical responses, providing evidence that DC
vaccination can elicit disease regression in CTCL patients.
Geskin et al. (2004) are currently conducting a second
DC vaccine clinical trial (Kingston et al., 2003). Therefore,
DC-based, specific immunotherapy aimed to activate tumor-
antigen-specific T-cells may represent a promising thera-
peutic strategy for CTCLs.
In most cancer patients, it is not possible to obtain
sufficient tumor tissue to generate the amount of antigens
needed for an effective and sustained immunization protocol.
In contrast to vaccinating with tumor lysates, using mRNA as
a source of antigens is advantageous because it allows
generation of large amounts of tumor antigen from limited
numbers of cells. It is possible to amplify mRNA from
microscopic amounts of tumor tissue, thus providing an
inexhaustible amount of antigen without the need to identify
the specific tumor antigens in each patient (Gilboa and
Vieweg, 2004). This approach should provide a solution for
patients with limited numbers of circulating Se´zary cells or
with disease limited to the skin.
There have been a few studies that utilized amplified
tumor mRNA as a source of antigens for loading of DCs in
cancer vaccine studies. Boczkowski et al. (2000) demon-
strated that DCs transfected with amplified tumor mRNA from
different cancer cells elicited strong cytotoxic T lymphocytes
(CTL) responses in the mouse model. Preclinical studies
using this strategy in human solid tumors (Heiser et al., 2001;
Jarnjak-Jankovic et al., 2005b), as well as hematological
malignancies (Jarnjak-Jankovic et al., 2005a), were promis-
ing. Clinical trials have been conducted in patients with
metastatic melanomas and showed that amplified tumor
mRNA DC vaccines were safe (Kyte et al., 2006; Markovic
et al., 2006). However, there are no published studies in
which total RNA or mRNA has been used as the source of
antigens in CTCL patients.
Foxp3þCD4þ CD25þ regulatory T cells (Tregs) are
thought to be one of main inhibitory mechanisms in deve-
lopment of tumor vaccine. It has been known that Tregs are
produced in the thymus (natural Tregs) but can also differen-
tiate from peripheral Foxp3CD4þ precursors (induced or
adaptive Tregs) by DCs (Yamazaki et al., 2007). Therefore,
the new generation of tumor DC vaccines is expected to
generate only effector CD8þ T cells without induction of
Tregs (Palucka et al., 2007).
In this present study, we hypothesized that tumor mRNA
obtained from Se´zary cells could be amplified to generate a
sufficient amount of biologically functional mRNA to be used
as the source of tumor antigen mixture for the stimulation of
DCs. We found that amplified tumor mRNA-transfected DCs
had the ability to generate antitumor T-cell responses ex vivo
without induction of Tregs.
RESULTS
Demographics of patients with SzS
Clinical and laboratory characteristics of 10 patients with SzS
in this study are summarized in Table 1. Nine of 10 patients
were stage IV and one with stage IIA with blood involvement.
The populations of CD4þCD26 T cells in blood were
considered as tumor cells (Jones et al., 2001). Eight patients
had 485% circulating CD4þCD26 cells and two patients
(patient nos. 1 and 4) had 450%. A dominant T-cell
receptor-Vb clone was identified in 7 of 10 patients, and
two patients had Vb12 clones, and two had Vb5.1. Eight of
10 patients had low number of CD8þ T cells (0.5–4.8%),
with a mean of 2.4%. All patients had normal number of
peripheral blood monocytes (3.0–11.0%). All patients had
received therapies before being recruiting into this study;
none had received chemotherapy, radiation, or immuno-
suppressive agents.
Generation of active monocyte-derived DCs from PBMCs of
SzS patients
Vaccination of cancer patients has been reported using
monocyte-derived DCs, and induced antitumor immunity
in hematological malignancies including MF (Maier et al.,
2003; Geskin et al., 2004; Kyte et al., 2006). To determine
the efficiency of generating active monocyte-derived DCs
from SzS patients, we sorted CD14þ monocytes from the
peripheral blood mononuclear cells (PBMCs) of SzS patients.
We obtained490% pure populations of CD14þ monocytes
comprising about 13% (3.0–19.6%) of PBMCs from SzS
patients.
A 5-day priming of CD14þ monocytes with GM-CSF and
IL-4, followed by a 48-hour incubation in either tumor-
necrosis factor (TNF)-a alone or a combination of cytokines
(IL-1b, TNF-a, IL-6, and prostaglandin E2 (ITIP)), was used to
generate mature DCs. Compared with addition of TNF-a
alone, ITIP induced higher expression of CD83, CD40, and
CD80 on mature DCs. CD86, HLA-ABC, and HLA-DR were
highly expressed on both mature DCs (495%). CD1a was
expressed at a low level (Figure 1a).
Allogeneic T-cell stimulatory capacities of DCs matured
by TNF-a and ITIP were next determined by mixed leukocyte
reactions (allogeneic mixed leukocyte reaction assay). As
shown in Figure 1b, DCs matured by ITIP showed much
stronger capacity to stimulate T cells to proliferate than
immature DCs and DCs matured by TNF-a alone at two ratios
of DCs (stimulator (S)) to T cells (responder (R)) of 1:20 and
1:5, respectively.
Active DCs produce high amounts of IL-12 during
maturation, and IL-12 plays a crucial role in induction of
antigen-specific primary CTL responses (Bontkes et al., 2005).
IL-12p70 production by DCs matured with both TNF-a and
ITIP at 24 or at 48 hours was very low (o40.0±10.0 pgml1;
Figure 1c), but there was an about threefold increase
(112.7±17.0 pgml1, Po0.01) in the level of DCs matured
by ITIP plus IFN-g at 48 hours. This suggests that IFN-g is
important for IL-12 production by monocyte-derived DCs
from SzS patients.
Amplification of tumor mRNA without loss of biological
function
Total RNA was extracted from peripheral blood lymphocytes
which had 485.0% circulating CD4þCD26 tumor cells.
In patient nos. 1 and 4, with lower numbers of circulating
CD4þCD26 cells, we first negatively selected tumor cells,
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the enriched CD4þCD26 cells (90% purity, data not
shown) were then used for total RNA extraction. The
concentration and quality of total RNA was determined with
Agilent Bioanalyzer and by agarose gel electrophoresis
(Figure 2a). Yields of total RNA from 107 cells were 4.4±
1.6 mg (1.6–6.9 mg), which is far below the amount required
for RNA transfection of DCs.
Laser-capture microdissection of individual tumor cells
was also attempted from sections taken from three patients
who had tumor biopsies. Tumor cells were identified by
cerebriform nuclears stained with Cresyl violet. The total
RNA extracted had low quality and insufficient quantity
(16.0–112.0 ng) for amplification.
The T7 in vitro transcription (IVT) amplification procedure
of Boczkowski et al. (2000) was then used to amplify tumor
mRNA and its efficiency was tested. The first cDNA was
synthesized from 0.3±0.1 mg of total RNA with modified
oligo-dT primer and T7 strand-switch primer. Each PCR
reaction generated 9.8±2.9 mg of cDNA. Subsequently, for
every 1 mg cDNA, a total of 51.3±15.9 mg of RNA was
produced by the T7 in vitro reverse transcription. Overall,
we were able to amplify tumor mRNA by about 2,600-fold
(Table S1).
Se´zary cells express the oncogenic transcription factor,
Twist, and the tyrosine kinase receptor, EphA4 (van Doorn
et al., 2004), which we used to confirm the specificity of total
RNA and amplified mRNA. The expected cDNA fragments
were identified, by reverse transcription–PCR (RT–PCR), for
Twist, EphA4, and b-actin in both original total RNA and
RNA that had been amplified (Figure 2b and c). Only the
sample from patient no. 4 lacked the EphA4 in the amplified
specimen as compared with original total RNA (Figure 2c).
Induction of antitumor CTLs by DCs transfected with amplified
tumor mRNA
The production of IFN-g and cytotoxicity are key components
for antitumor CTLs induced by DC tumor vaccines. To deter-
mine induction of antitumor CTLs, CTLs primed by RNA-
transfected, DCs were co-incubated with target tumor cells
from both the same and different patients. The induction
of antitumor IFN-g-producing CTLs was assayed by enzyme-
linked immunosorbent spot (ELISPOT). Autologous RNA-
transfected DCs were able to induce antitumor IFN-g-
producing CTLs in 7 of 10 subjects (Figures 3 and 4a, patient
nos. 1,2, 6, 7, 8, 9, and 10), which were inhibited with the
blocking antibody to the HLA class I (Figure 3c, patient no.
8). Variable amounts of IFN-g-producing CTL were observed
when allogeneic tumor cells were used as target cells,
suggesting the presence of conserved SzS antigens (data not
shown).
Autologous RNA-transfected DCs induced a 2- to 32-fold
increase in IFN-g-producing CTLs ex vivo as compared with
control, non-transfected DCs (Figure 4). There was no induc-
tion of IFN-g-producing CTLs in patient no. 3 who had the
lowest number of CD8þ T cells (0.5%) in the peripheral
blood. There was more induction of IFN-g-producing CTLs by
non-transfected DCs than transfected DCs in one subject
(patient no. 5) due to excessive electroporation current
impacting cell viability of transfected DCs. A low level of
nonspecific induction of CTLs was found with non-trans-
fected DCs in the majority of assessed subjects (Figures 3
and 4).
Granzyme B (GrB) is a specific mediator released by
CTLs. Release of GrB has been used as an indicator of
the cytotoxicity of CTLs in cancer vaccine trials (Shafer-
Weaver et al., 2006; Malyguine et al., 2007). In our study,
the induction of antitumor GrB-producing CTLs by RNA-
transfected DCs was found in 6 of 9 subjects (Figure 4b,
patient nos. 1, 2, 4, 6, 8, and 10), and was 1.5-to 3-fold more
than that seen in CTLs primed by mock DCs. The induction of
IFN-g-producing CTLs and GrB-producing CTLs was induced
concurrently in five subjects. In two subjects (patient nos. 3
and 5), induction of both IFN-g and GrB-producing CTLs was
unsuccessful. Patient no. 4, with the highest CD8þ counts,
had significant induction of GrB-producing CTLs, but only
few IFN-g-producing CTLs.
Using 51Cr release assay, we confirmed that CTLs primed
by tumor RNA-transfected DCs were able to kill more target
Table 1. Characteristics of patients with SzS
Pt no. Age Gender Stage
Monocyte
(2.0–7.0%)
CD4+CD26 T cells
(1.9–36.3%)
CD3+CD8+ T cells
(7.4–39.9%) TCR Vb (%)
Therapies
ongoing
1 56 F IIA 6.2 59.9 7.5 — Diclox, ECP
2 71 M IVA 8.0 95.2 2.2 — Diclox
3 34 M IVB 3.0 94.9 0.5 — None
4 89 M IVA 9.0 58.7 21.1 Vb17(63.2) Targ, ECP
5 76 M IVB 11.0 85.7 4.8 Vb5.1(82.9) Diclox
6 56 M IVB 7.0 87.7 3.2 Vb12(87.6) None
7 50 M IVB 8.0 86.3 2.4 Vb8(98.0) None
8 50 F IVB 9.0 86.2 1.9 Vb2(90.0) Targ
9 83 M IVA 8.0 93.7 1.7 Vb12(96.0) Targ, Diclox
10 57 M IVB 4.0 85.6 2.5 Vb5.1(84.0) Targ, ECP, IFN-a
Diclox, dicloxacillin; ECP, photopheresis; F, female; M, male; ND, not done; Pt, patient; SzS, Se´zary syndrome; Targ, Targretin.
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cells compared with that against control cells at two different
effector to target ratios (Figure 3d).
Both CD3þCD8þ T cells and CD4þCD25þ T cells
expanded after RNA-transfected DCs stimulation, not including
Tregs
To assess the possibility of induction of Tregs by DCs,
we examined the percentage of CD3þCD8þ and CD4þ
CD25þ T cells before and after DC stimulation and also the
level of foxp3 mRNA, a Treg marker. The CD3þCD8þ
T cells were expanded after DC stimulation in 4 of 5 pairs
of samples (Figure 5a and b, patient nos. 4, 7, 8, and 10). All
five pairs of samples showed dramatically increased CD4þ
CD25þ T cells (Figure 5c), but expression of foxp3 decrea-
sed after DC stimulation in 2 of 2 pairs of samples (Figure 5d,
patient nos. 7 and 10). These data indicate that both CD3þ
CD8þ and CD4þCD25þ T cells are expanded after DC
stimulation, but Tregs are not induced.
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Figure 1. Characterization of monocyte-derived DCs from SzS. (a) The immunophonetypic profile of DCs. DCs generated form CD14þ monocytes from SzS
patients in the presence of GM-CSF and IL-4 for 5 days (iDCs) and matured with TNF-a (mDC(TNF-a)) or with the combination of TNF-a, IL-1b, IL-6, and
prostaglandin E2 (mDCs(TNF-a, IL-1b, IL-6, and prostaglandin E2)). The diagram shows the upregulated expression of CD40, CD83, HLA-ABC, and CD80 and
CD86 over time, downregulated expression of CD14, and no change of CD1a. The results are from patient no. 1. (b) Allogeneic T-cell stimulatory capacities
of monocyte-derived DCs from SzS by mixed leukocyte reaction. A total of 5104 allogeneic T cells were incubated with 10,000 and 2,500 fresh immature
DCs (iDC), TNF-a matured DCs (mDC(TNF-a)), or ITIP-matured DCs (mDC(ITIP)). Incubation with monocytes was used as negative control. The data
presented are the mean±SD of the experiment performed in triplicate in patient no. 1. (c) The production of IL-12p70 by monocyte-derived DCs from SzS;
0, 24, and 48-hour culture supernatants from DCs treated with TNF-a alone, ITIP, and ITIP with IFN-g, were examined by ELISA specific for IL-12 p70.
The graph shows the mean of triplicate values. Data are results from patient no. 2.
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DISCUSSION
In this preclinical feasibility study, autologous monocyte-
derived DCs were generated from the peripheral blood of
patients with SzS and used as antigen-presenting cells for
generation of antitumor T-cell responses. We found that DCs
transfected with amplified tumor mRNA were able to induce
antitumor IFN-g-producing CTLs in 7 of 10 tested subjects,
and GrB-producing CTLs in 6 of 9 tested subjects. The induc-
tion of antitumor CTLs, ex vivo, by RNA-transfected DCs in a
large fraction of our subjects confirms that the RNA isolated
from Se´zary cells can be amplified to generate a sufficient
amount of biologically functional mRNA. Meanwhile, we
showed that both CD3þCD8þ and CD4þCD25þ T cells
are expanded after DC stimulation, but Tregs are not induced,
as determined by expression of Foxp3. In addition, we
confirmed that the SzS-specific oncogenic transcription
factor, Twist, and the tyrosine kinase receptor, EphA4, trans-
cripts were expressed in tumor RNA samples. Laser-capture
microdissection of tumor cells in a small number of frozen
sections was less successful for isolating good quality and
yield of mRNA for amplification.
Using autologous tumor-derived antigenic mixtures offers
superior strategies for eliciting antitumor immunity in cancers
for which no dominant shared antigen has been identified.
Studies have indicated that despite presence of only a small
proportion of relevant tumor antigens in the mixture, the
polyvalent vaccine strategy is remarkably effective in
stimulating antitumor immunity in vitro and in vivo (Fields
et al., 1998; Maier et al., 2003). A number of tumor antigens
are known to be variably expressed in CTCL tumor cells, but
there have been no dominant shared antigens identified to
date (Eichmuller, 2002). The mRNA has been reported to be a
more effective and simpler form of tumor antigens for use in
stimulation of DCs as compared to tumor lysates or peptides
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(Weissman et al., 2000). In this study, we were able to
generate sufficient amounts of tumor mRNA from total RNA
of Se´zary cells in all subjects with T7 IVT amplification,
including two SzS patients who had low percentages of
circulating CD4þCD26 cells. Our findings are consistent
with results from Gilboa’s group who first described the T7
IVT amplification of RNA in DC tumor vaccination studies
(Boczkowski et al., 2000; Gilboa and Vieweg, 2004). Our
data suggest that T7 IVT amplification of tumor mRNA is a
solution to vaccinate SzS patients who have a limited
circulating tumor cells for generating sufficient amount of
antigens for the stimulation of DCs.
The tyrosine kinase receptor, EphA4 and the potentially
oncogenic transcription factor, Twist, were reported highly
and selectively expressed in tumor cells of patients with SzS
and are potential tumor-specific antigens for SzS vaccination
(van Doorn et al., 2004). To confirm that amplified tumor
mRNA is biologically functional, we examined transcripts of
Twist, EphA4, and housekeeping gene b-actin in native tumor
total RNA and paired amplified mRNA. We found that the
transcripts of b-actin and Twist are maintained throughout
amplification, and Epha4 was expressed in all except one
of amplified mRNA samples. These data suggest that mRNA
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Figure 5. The percentage of CD3þCD8þ T cells and CD4þCD25þ
T cells in peripheral blood lymphocytes before and after DC stimulation
and expression of foxp3 mRNA. (a) The peripheral blood lymphocytes
before and after DC stimulation were stained for CD3þCD8þ T cells and
CD4þCD25þ T cells by dual-color immunofluorescent staining. The plots
were from patient no. 7. (b) The increase in percentage of CD3þCD8þ
T cells were found in four of five pairs of tested samples (patient nos. 4, 7, 8,
and 10). (c) The increase in percentage of CD4þCD25þ T cells were
found in all five tested pairs. (d) Total RNA was extracted from peripheral
blood lymphocytes before and after DC stimulation and the levels of foxp3
mRNA were assessed by real-time quantitative RT–PCR. The relative
expression of foxp3 was normalized to glyceraldehye-3-phosphate
dehydrogenase . The decrease in expression of foxp3 was found in
2 of 2 tested pairs (patient nos. 7 and 10). *Po0.05.
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from Se´zary cells can be amplified without loss of biological
function, but there is still some possibility of failure to
amplify. A clinical trial recently conducted with stage-IV
malignant melanoma patients has demonstrated that clinical-
grade DCs transfected with tumor-derived in vitro amplified
mRNA was feasible and safe (Markovic et al., 2006).
Monocyte-derived DCs have been used successfully in
two reported clinical trials for vaccinating patients with CTCL
patients (Maier et al., 2003; Geskin et al., 2004). In our study,
monocyte-derived mature DCs did express high levels of
surface CD83 and co-stimulatory molecules and were able to
stimulate allogeneic T cells to proliferate. But we found a low
level of IL-12p70 production by monocyte-derived DCs from
SzS patients when matured with conventional maturation
cytokines (TNF-a or ITIP). However, IL-12p70 production by
monocyte-derived DCs was restored by additional IFN-g
treatment during DC maturation. Previous studies have
reported deficient IL-12 production by PBMCs from patients
with SzS; low CD11cþ DCs were thought to be responsible
for this defect (Rook et al., 1995; Wysocka et al., 2002). Our
findings imply that combining IFN-g or IL-12 with DC
vaccination in SzS patients may be necessary to generate
CTL responses in future trials. Recently, a clinical trial of
toll-like receptor agonist (oligo-deoxynucleotides with CpG
motifs, CpG ODN) demonstrated an enhancement of the host
immune response in CTCL patients (Wysocka et al., 2004).
Sporri et al. also reported that the most optimal activation of
DCs requires toll-like receptor signaling (Sporri and Reis e
Sousa, 2005). Further studies are needed to assess the effects
of toll-like receptor activation of DCs compared with
inflammatory signal activation like ITIP.
A major obstacle in developing an active immuno-
therapeutic approach to cancer is induction of tolerogenic
DCs and Treg, which suppress the development of protective
effector T-cell responses. In our study, we found dramatic
increase in the number of CD4þCD25þ T cells after DC
stimulation, but without expression of Foxp3. Continuous
incubation with IL-2 is known to cause T-cell activation and
upregulate the expression of CD25, the a-chain of the IL-2
receptor. Recently, a study reported that the recombinant IL-2
diphtheria toxin conjugate DAB389IL-2 (denileukin diftitox
(Ontak)) mediated elimination of Tregs followed by vaccina-
tion with RNA-transfected DCs, and significantly improved
the stimulation of tumor-specific T-cell responses in patients
with renal cell carcinoma compared with vaccination alone
(Dannull et al., 2005).
The majority of our SzS patients had heavy tumor burdens
combined with low numbers of CD8þ T cells in their blood,
which are poor prognostic indicators. Nonetheless, two-
thirds of our subjects demonstrated the induction of antitumor
immunity ex vivo and this indicates that amplified tumor
mRNA-transfected DCs will induce antitumor CTLs. The
exception was patient no. 3 who had the lowest number of
CD8þ cells and no induction of a CTL response. This
supports the concept that CD8þ T cells are important for
inducing antitumor immunity and the possibility that ex vivo
expansion of antitumor CTLs may be needed for vaccination
to be successful. Furthermore, selection of SzS patients with
sufficient numbers of CD8þ T cells or lower tumor burden
may be optimized for vaccination responses. We speculate
that initial-stage patients or advanced stage patients following
good responses to therapies or following allogeneic human
stem cell transplantation with minimal residual disease might
be the most likely to benefit for this immunotherapeutic
strategy.
In summary, the results of this study provide an attractive
rationale for the development of clinical vaccination proto-
cols for patients with SzS or other forms of CTCL. The strategy
of using DCs transfected with amplified tumor mRNA has the
advantage of requiring only small amounts of tumor cells and
does not require a specific relevant antigen profile for each
patient.
MATERIALS AND METHODS
Patients
The study was conducted at the University of Texas MD Anderson
Cancer Center from January 2004 to May 2007. The Institutional
Review Board of MD Anderson Cancer Center approved all
described studies. Participants gave their written informed consent.
The study was conducted according to Declaration of Helsinki
Principles. Patients were either newly diagnosed or had been
previously diagnosed and staged as SzS according to the WHO-
EORTC classification (Willemze et al., 1997). Eligibility criteria for
patient recruitment were the following: age 418 years old; high
white blood cell count, normal monocyte percentage, and no
anemia; more than 50% CD4þCD26 cells in peripheral blood.
Sixty to 80ml of venous blood was collected from patients with SzS
either prior to extracorporeal photopheresis or during clinic visits at
University of Texas MD Anderson Cancer Center.
Laser-capture microdissection
Tumor specimens were obtained and frozen immediately on the dry
ice after biopsies from three patients with tumors. Frozen sections
were obtained and stained with Cresyl Violet from laser capture
microdissection staining kit (Ambion, Austin, TX). Tumor cells were
identified microscopically and microdissected in the manner of
positive selection (Heiser et al., 2001). The identified tumor cells
were transferred a 0.5-ml tube. Total RNA was then isolated using
the RNAqueous-Micro kit according to the manufacturer’s instruc-
tions (Ambion).
PBMCs isolation and DC generation
PBMCs were separated by Histopaque-1077 density-gradient cen-
trifugation. CD14þ monocytes were sorted from PBMCs using
MACS CD14 positive selection kit (Miltenyi Biotec Inc., Auburn, CA).
The monocytes were then suspended in AIM-V medium containing
2% human serum with 1,000Uml1 IL-4 and 1,000Uml1 GM-CSF
at 5 105 or 1 106 cellsml1 at 37 1C in 5% CO2 for 5–6 days
to generate immature DCs. Cells were matured for 48 hours with
TNF-a or a cytokine cocktail of IL-1b at 1,000Uml1, TNF-a at
2,000Uml1, IL-6 at 1,000Uml1, and prostaglandin E2 at
1mgml1 (ITIP) (R&D Systems, Minneapolis, MN).
Flow cytometry
Monocytes, DCs, and T cells was immunophenotyped using
the following FITC and phycoerythrin-conjugated antibodies,
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respectively: CD1a, CD3, CD4, CD14, CD8, CD25, CD40, CD80,
CD83, CD86, HLA-ABC, and HLA-DR (BD Biosciences, San Jose,
CA). FITC- or phycoerythrin-conjugated IgG1k, IgG2a were used as
isotype controls. Single-cell suspensions were incubated with anti-
bodies for 30minutes on ice, washed once in phosphate-buffered
saline, pH 7.2, and analyzed with a FACScan flow cytometer
using CellQuest software as per manufacturer instructions (Becton
Dickinson, San Jose, CA).
Mixed-leukocyte reactions
Allogeneic T cells (5 104) were incubated with 10,000 and 2,500
fresh immature DCs, TNF-a-matured, or ITIP-matured DCs for
5 days. T-cell proliferation was measured with a liquid scintillation
counter following 18-hour incorporation of 3H-labeled thymidine
(5Cimmol1; Amersham Bioscience, Piscataway, NJ). Incubation
with monocytes was used as a negative control.
Enzyme-linked immunosorbent assay (ELISA)
Supernatants were harvested at 0, 24, and 48 hours during DC matu-
ration. IL-12 p70 was then measured using the BD OptEIA Human
IL-12 (p70) ELISA kit according the instructions of the manufacturer
(BD Biosciences).
Total RNA extraction
Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA)
from peripheral blood lymphocytes. For patient nos. 1 and 4, CD4þ
CD26 cells were first enriched using the EasySep CD4þCD26
isolation kit (Stem Cell Technology, Vancouver, BC, Canada).
The concentration and quality of total RNA and amplified mRNA
were determined by spectrometry and Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA).
T7 IVT amplification
The mRNA was amplified using T7 IVT amplification described
by Boczkowski et al., (2000).
Conventional RT–PCR
The first cDNA was synthesized with an oligo (dT)12–18 primer
using SuperScript II reverse transcriptase (Life Technologies Inc.,
Gaithersburg, MD). The primers for EphA4 and Twist, and cycle
parameters for PCR, were used as previously described (van Doorn
et al., 2004). The primers for b-actin were purchased from Promega
(Madison, WI). The resulting cDNA fragments for EphA4, Twist, and
b-actin were 96, 107, and 285bp, respectively. The specificity of
PCR products was confirmed by 2% agarose gel electrophoresis.
Real-time quantitative RT–PCR
The relative level of Foxp3 mRNA was measured using real-time
quantitative RT–PCR with an ABI Prism 7000 Sequence Detection
System using the default protocol by the manufacturer (Applied
Biosystems, Foster City, CA). Pre-formulated TaqMan primer and
probe for Foxp3 (Hs00203958) were used. The relative levels of
foxp3 expression were normalized to endogenous control gene,
glyceraldehye-3-phosphate dehydrogenase (Hs99999905).
Electroporation of tumor mRNA of DCs
Immature DCs were harvested on day 5 or 6 and resuspended at
4 107ml1 in phosphate-buffered saline. Cells were electrotrans-
fected with amplified mRNA at 5mg per 106 cells. Electroporation
was performed using the Gene Pulser Xcell Eukaryotic System
(Bio-Rad, Hercules, CA) in a 0.4-cm gene-pulser cuvette with 300V
of voltage and 150mF of capacitance. Amplified mRNA-transfected
DCs and mock control DCs were transferred to AIM-V medium with
IL-4 and GM-CSF incubated for 1 hour at 37 1C. ITIP was then added
for 48 hours for maturation.
Induction of antitumor cytotoxic T lymphocytes
A total of 1.0 106 peripheral blood lymphocytes were stimulated
with 1.0 105 autologous RNA-transfected DCs and mock control
DCs for 7 days with rhIL-2 at 100Uml1 (R&D Systems).
Re-stimulation was performed every 7 days for two or three
times. Following the final stimulation, cells were incubated for
one additional week prior to cell harvest. 51Cr release assay and
induction of IFN-g-producing CTLs and GrB-producing CTLs were
then analyzed by ELISPOT assay.
ELISPOT assays
Nitrocellulose 96-well plates were coated overnight at 4 1C with
mouse anti-human IFN-g or GrB antibody (5.0 mgml1), respectively
(BD Biosciences). The patient’s own CD4þCD26 cells were used
as target cells at 1.0 105ml1 and CD4þCD26 cells from
another patient were used as controls. Effector cells induced by
RNA-transfected DCs or mock DCs were harvested. Target cells and
a series diluted effecter cells were plated in duplicate onto antibody-
coated plates at 37 1C overnight. Cells were removed; wells then
incubated with biotinylated anti-human IFN-g or GrB at 2.0 ml ml1,
followed by treatment with streptavidin–horseradish peroxidase and
AEC substrate. Inhibition of HLA class I was performed by incubation
of target cells for 1 hour with mAb W06/32 (20.0 mgml1). Spots
were counted using ImmunoSpot Analyzer (CTL Analyzers, LLC,
Cleveland, OH).
The 51Cr release assay for CTL activity
Tumor mRNA-transfected DCs (target cells) and mock control DCs
were labeled overnight at 371 C with 100 mCi 51Cr per 106 cells
(Perkin-Elmer, Boston, MA). Target cells were then added to 96-well
V-bottom plates which effector cells had been added, centrifuged,
and then incubated for 4–6 hours at 37 1C. All reactions were carried
out in 100ml per well RPMI-1640. Supernatants (45 ml per well) were
transferred to Luma96 plates (Perkin-Elmer). Following overnight
evaporation, plates were read with a TopCount NXT (Perkin-Elmer).
Specific lysis (SL) was finally calculated as follows: SL¼ (sample
valuespontaneous lysis value)/(maximum lysis valuespontaneous
lysis value) 100%.
Statistical analysis
Statistical significance of results was determined by w2-test and t-test.
Differences between experimental groups were considered signifi-
cant at Po0.05.
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